HRS In Brief
This article was originally published in The Gray Sheet
Executive Summary
Data highlighted earlier this month at the Heart Rhythm Society annual conference in Boston include results for new ablation systems, quadripolar leads and antibacterial cardiac implant wraps.
You may also be interested in...
Medtronic, St. Jude Launch New Quadripolar Devices
Medtronic has launched two more Attain Performa left ventricular quadripolar leads for the Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators following FDA approval announced Dec. 11. On the same day, St. Jude announced CE mark of the Quadra Allure MP cardiac resynchronization therapy pacemaker, the first quadripolar CRT-P with MultiPoint pacing.
Research Briefs: CardioFocus Trial Enrollment; Nerve Stim For Headaches; Cataract Removal
Enrollment in CardioFocus’ U.S. pivotal trial of the HeartLight endoscopic atrial fibrillation ablation system is complete. A small study shows that small wires implanted in the head may cure chronic headaches. Biolase and Auris announce plans to build a cataract removal robot.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.